Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma
A baseline NLR ≥ 2.9 and PLR ≥ 148.0 may serve as predictive factors for poor OS and PFS in uHCC patients receiving Atezo-Bev-TACE treatment. Furthermore, the Atezo-Bev-TACE regimen demonstrates good efficacy and safety in the clinical management of uHCC patients.
Authors
- Shugeng Zhang (ORCID: https://orcid.org/0000-0001-9832-9784)
- Lianxin Liu (ORCID: https://orcid.org/0000-0002-3535-6467)
- Björn Nashan (ORCID: https://orcid.org/0000-0001-7587-9935)
- Shaobo Zhang (ORCID: https://orcid.org/0000-0003-2549-7247)
- Zebin Zhu (ORCID: https://orcid.org/0000-0002-2630-7604)
Institutions
- University of Science and Technology of China (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1007/s00262-025-04058-4
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97
Funders
- Anhui Provincial Department of Education